New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
- More than one quarter (26%) of primary care patients 40 years of age and
older with a smoking history and symptoms of chronic bronchitis had
airflow obstruction consistent with a diagnosis of COPD
- Percentages were greater with increasing patient age and smoking history
Midwest Medium, Large-Cap Life Sciences Had Solid 2003
CHICAGO Last week, as part of our 2003 year-end biotech wrap up, I reviewed the performance of the Midwest biotech publicly traded companies. The region had
an incredible year for this group.
This week, lets a look at how the medium and large-cap Midwest life science companies fared in 2003. T...
Despite the three Gs, the Wisconsin Legislature had a productive session
MADISON If you asked Wisconsin citizens what they knew about the work of the Wisconsin Legislature in the past year or so, the answers would likely include God, guns and gays, alliterative shorthand for high-profile bills dealing with religion, concealed weapons and same-sex marriage.
Imagine the possibilites if you had very high-speed broadband
Silly me, getting all excited about the DSL line that delivers data at 1.5M bit/sec (and up to 3M bit/sec on a good day) downstream. Foolish of me to be thrilled to get great performance from the fixed broadband wireless that reaches my coastal home. Until I heard from Samsung's GS Choi, president ...
What if Jobs and Gates had teamed up?
The tech industry buzzed last week over what many deemed a historic meeting between Steve Jobs and Bill Gates on the stage of the Wall Street Journal's schmooze-fest titled D: All Things Digital. While some might have wanted fireworks, the two icons of the PC Age were cordial and humble (a ...
Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading
...rsonal connection because his grandmother recently had
the procedure performed with a life-changing, pain...patients who received the vertebroplasty procedure had
reductions in pain of 2.3 and 3.0 points in the tw...patients who received the vertebroplasty procedure had
greater reductions in pain, although this was not ...
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
... 2008. These decreases were primarily due to lower operating expenses offset by lower revenues.
Liquidity and Capital Resources
approximately $3.1 million in cash and cash equivalents, and $473,711 in restricted cash as of June 30, 2009. Based on our current operating plan, we ...
Novavax Reports Second Quarter 2009 Financial Results
... notes. The notes carried a coupon rate of 4.75% payable semi-annually and had
a maturity date of July 15, 2009. The company retired $17.0 million of the...scontinued operations of $1.1 million.
As of June 30, 2009, Novavax had
$31.2 million in cash and short-term investments (including auction rate se...
Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
...th respect to the development and commercialization of our Cartilage Repair Device," he concluded.
The Company has previously announced that it had
submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to study the use of the Company's uniqu...
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
... and $112,524, respectively.
As a development stage biopharmaceutical company, Catalyst has no revenues to-date. At June 30, 2009, the Company had
cash and cash equivalents totaling $6.3 million and no long-term debt.
"We have sufficient cash to complete the analysis of the results from ou...
American Oriental Bioengineering Reports Second Quarter 2009 Financial Results
... per diluted share. In the prior year's second quarter,
net income per diluted share was approximately $0.18.
As of June 30, 2009, the Company had
$100.7 million in cash and generated
approximately $22.9 million of operating cashflow during the second quarter of
Mr. Tony Liu, Chairma...
ThermoGenesis Announces Expanded Collaboration With Celling Technologies
...has delivered in advancing the application of regenerative medicine therapy for patients undergoing spinal fusion procedures match the expectations we had
when we agreed to partner with ThermoGenesis. We are delighted to be implementing programs with them to expand the use of the MXP in the treatment of ...
Microbix Sales Grow 22% For Nine Months
...or nine months ended June 30, 2009, Microbix Biosystems Inc. (TSX:MBX) announced strong sales and a significantly reduced burn rate. The third quarter had
a small sales retraction that was related to timing of orders and changing exchange rates. The forecast is for continued growth in sales.
"The 22% s...
Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
...seasoned and talented executive with valuable experience in financial management, corporate strategy and fundraising, and investor relations. Fred has had
considerable experience as a public company CFO and has raised significant funds in the capital markets. In addition, he enjoys a strong reputation in...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
...pplication (MAA) is also progressing very well; we had
a successful pre-submission meeting with the EMEA ...transaction.
As of June 30, 2009, InterMune had
cash, cash equivalents and available-for-sale secu...ril 21, InterMune reported that the INFORM-1 study had
been expanded by three additional cohorts to explo...
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
...s 46,238,618 for the first half of 2008.
Cash, Cash Equivalents and Available for Sale Securities
As of June 30, 2009, SEQUENOM had
total cash, cash equivalents and short- and long-term marketable securities of $69.3 million and $7.5 million in accounts receivable.
OncoGenex Reports Second Quarter 2009 Financial Results
...are no preferred shares outstanding.
The Company had
$5.7 million in cash, cash equivalents and short-t... the second quarter, the Company announced that it had
completed a registered direct offering of 475,000 ...cted to be approximately $9.4 million. The Company had
6,027,631 shares outstanding as at August 5, 2009....
Telik Announces Second Quarter 2009 Financial Results
...marily due to lower headcount, reduced research and clinical trial expenses and lower stock-based compensation expense.
At June 30, 2009, Telik had
$50.6 million in cash, cash equivalents and investments including restricted investments, compared to $63.5 million at December 31, 2008.
The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict
...ve gout. The doctor claimed that she told him she had
gout and described pain in her toe consistent with...jected.
Prior to the injury, the Plaintiff had
been quite healthy and active. As a result of the ...rse of action been taken, my client would not have had
to suffer this horrible, disfiguring disease." Pr...
Transposagen Creates a Rat Model of the Human Immune System
... immune system in the near future," said Dr. Eric Ostertag , CEO of Transposagen.
SCID can also affect humans, such as the "Bubble Boy," who had
to live inside of a sterile environment to reduce the likelihood of contracting a fatal infection. The SCID mouse has been one of the most often used ...
PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
...arger natural biologic molecules. Out of the more than one million small molecules he studied, he ultimately found 4 that protected the cells and that had
profiles suitable for further drug development. Once these molecules were identified, Dr. Longo formed PharmatrophiX as a biotech company in order to ...
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
...United States Food and Drug Administration ("FDA") had
granted 510(k) clearance for the Option(TM) Inferi...re Corporation. In June 2009, we announced that we had
entered into license, distribution, development an...cure and a further $0.6 million of the loan, which had
been accrued at June 30, 2009, was drawn upon subs...
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
...re is due to an increase in the number of shares outstanding and a reduction in research and development and financing as described above.
approximately $12.0 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of June 30, 2009. This does not in...
New clues about a hydrogen fuel catalyst
... from ammonia borane. To find out, the researchers had
to combine experimental work with theoretical work... experiments were like puzzle pieces that the team had
to fit together.
To put the puzzle together, th...a matched very well, suggesting the structure they had
come up with was very close to reality.
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
...he second quarter ended June 30, 2009.
At June 30, 2009, the Company had
cash, cash equivalents, short-term investment securities and interest recei...5 million at December 31, 2008. In addition, at June 30, 2009, the Company had
$7.1 million of auction rate securities which are classified as long-term i...
PDI Reports 2009 Second Quarter Financial Results
...rcialization contract. As of June 30, 2009, the Company's cash equivalents were predominately invested in Treasury money market funds and the Company had
no commercial debt.
As previously announced, PDI will hold a conference call today, to discuss financial and operati...
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
...An analysis of the Phase 2 and Phase 2 extension study biopsies using the improved methodology demonstrated that all of the evaluable baseline samples had
detectable interstitial capillary GL-3 and that reductions were observed in eight of the nine responders.
It is expected that approximately 3...
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... - On June 1, 2009 Shire announced that the FDA had
approved a change to
the prescribing informa... product labeling.
- By July 24, 2009 VYVANSE had
achieved a US ADHD market share
of 12.3% bas...DHD
- On April 2, 2009 Teva announced that it had
commercial shipment of its authori...
Pharmacyclics, Inc. Rights Offering Oversubscribed
The subscription agent has informed the Company that based on a preliminary tabulation, as of the close of the offering the Company had
received valid subscriptions from approximately 375 participants for the purchase of in excess of the 22,500,000 shares offered. The total gross proc...
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
...t-term investments of $51.2 million.
"During the second quarter, we had
the first oral presentations of our North American Phase 3 fidaxomicin data...xperienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had
a higher global cure (cure with no recurrence within four weeks) compared t...
NxStage Reports Second Quarter 2009 Financial Results
...GE credit facility. Excluding these one-time items, cash usage from operations was $5.0 million.
For the second quarter of 2009, the Company had
an Adjusted EBITDA loss of $3.4 million, adjusted for stock-based compensation, deferred revenue recognized and other non-recurring expenses, compared...
SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
...ities to support regulatory filings for S6973 in the U.S. and elsewhere.
In addition to the activities regarding the Sweet Enhancers, Senomyx had
notable progress in its Bitter Blockers Program during the past quarter. Recent taste tests demonstrated that the Company's bitter blockers can provi...
Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
...al meeting in the fall of 2008 confirming that there were no post operative issues or complications from the use of Quill SRS in a patient series that had
grown to 150 patients reviewed to that date. "Bidirectional barbed sutures greatly facilitate laparoscopic suturing. Further evolution and incorporati...
Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
The clinical trial began on July 22, 2009 and a total of 1,614 volunteers,
including 101 elders, 706 adults, 404 juvenile and 403 children, had
the first shot of the vaccine through July 25. During the three-day
observation period, none of the volunteers participating in Sinovac's cl...
Biotech Hot in July Driven by Positive Drug Data and Acquisitions
...r 50 years. Patients taking Benlysta plus a standard treatment for one year had
reduced symptoms - including pain, rashes and infections - compared with pa...ata the publication reports that at the end of July this group of companies had
an aggregate market cap of $345 billion (up 7 percent for the month). Also:...
Five Questions About Protopic (tacrolimus) Ointment
...ed that a significantly greater number of patients had
at least 90% or more improvement with Protopic, ba...iatric and adult eczema patients who used Protopic had
an itch reduction 5 times greater than those who u...ber of people who have used Protopic Ointment have had
cancer (for example, skin or lymphoma). However, ...
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
...ovel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells.
In June, Micromet announced that the company had
achieved its primary endpoint in an ongoing Phase 2 study of ALL patients. The company presented data at the the 14(th) Congress of the European Hemat...
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
...isease progression. Nine of the 10 living patients had
stage IIIb NSCLC upon entry to the trial, while one had
stage IV disease. Six of the 10 living patients had
a complete response to their first-line chemothera...
Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
including 101 elders, 706 adults, 404 juvenile and 403 children, had
the first shot of the vaccine through July 25. During the three-d...clinical study. In
June 2009, Sinovac announced that the Ministry of Health had
made an initial
order of 4 million doses of Panflu, which is expected to be...
Bacteria pack their own demise
...ions at VUB, have applied their relentless dedication to the study of the precise structure and function of the toxin-antitoxin complex, a system that had
not been the focus of much interest in the past. Only in the last couple of years the rest of the scientific world come to realize its importance and ...